| 摘要 |
<p>The object of the present invention is the use of substance P antagonists, particularly the use of non-peptide NK1 receptor antagonists for the treatment of cancer and more specifically on human melanoma, neuroblastoma, glioma, human KM-H2 Hodgkin's lymphoma, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.</p> |
